Ember
Senior Member
- Messages
- 2,115
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
As I understand it the point is to follow patients in the early phase and see what happens, how it changes. This may show the transition mechanisms, or at least features of a change to the longer term condition.So they are looking at their cytokine work as a biomarker - but I guess only for patients ill less than 3 years.
The same cytokines that were elevated in short duration patients were dampened in long duration patients, so if the findings of the initial study are validated and a panel test is developed, it could still be used for long duration patients to confirm diagnosis, which would probably help with insurance claims etc.So they are looking at their cytokine work as a biomarker - but I guess only for patients ill less than 3 years.